Qualigen Therapeutics Enters Material Definitive Agreement
Ticker: AIXC · Form: 8-K · Filed: Feb 22, 2024 · CIK: 1460702
| Field | Detail |
|---|---|
| Company | Qualigen Therapeutics, INC. (AIXC) |
| Form Type | 8-K |
| Filed Date | Feb 22, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $1,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-action
TL;DR
**Qualigen Therapeutics just signed a major deal, expect potential shifts!**
AI Summary
Qualigen Therapeutics, Inc. filed an 8-K on February 22, 2024, reporting an event that occurred on February 15, 2024. The filing indicates an "Entry into a Material Definitive Agreement" and includes "Financial Statements and Exhibits." The document provides standard company information such as its incorporation in Delaware and its business address in Carlsbad, California.
Why It Matters
This filing signals a significant business development for Qualigen Therapeutics, potentially impacting its strategic direction, financial health, or operational capabilities.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement without disclosing details, creating uncertainty about its nature and potential impact.
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant
- Delaware (company) — State of incorporation
- Carlsbad, California (company) — Principal executive offices location
- February 15, 2024 (date) — Date of earliest event reported
- February 22, 2024 (date) — Filing date
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 15, 2024.
What is the primary reason Qualigen Therapeutics, Inc. filed this 8-K?
Qualigen Therapeutics, Inc. filed this 8-K due to an "Entry into a Material Definitive Agreement" and to include "Financial Statements and Exhibits."
Where are Qualigen Therapeutics, Inc.'s principal executive offices located?
Qualigen Therapeutics, Inc.'s principal executive offices are located at 5857 Owens Avenue, Suite 300, Carlsbad, California 92008.
What is the Commission File Number for Qualigen Therapeutics, Inc.?
The Commission File Number for Qualigen Therapeutics, Inc. is 001-37428.
What is the state of incorporation for Qualigen Therapeutics, Inc.?
Qualigen Therapeutics, Inc. is incorporated in Delaware.
Filing Stats: 739 words · 3 min read · ~2 pages · Grade level 11.5 · Accepted 2024-02-22 16:10:41
Key Financial Figures
- $1,000,000 — Pan-RAS would pay us an upfront fee of $1,000,000 in cash. In addition, Pan-RAS would bec
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex10-1.htm (EX-10.1) — 70KB
- 0001493152-24-007562.txt ( ) — 295KB
- qlgn-20240215.xsd (EX-101.SCH) — 3KB
- qlgn-20240215_lab.xml (EX-101.LAB) — 33KB
- qlgn-20240215_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: February 22, 2024 By: /s/ Michael S. Poirier Michael S. Poirier, Chief Executive Officer